News

The global arteriovenous fistula (AVF) treatment market is projected to reach approximately USD 868.8 million in 2025 and ...
(Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that the results from its V007 ...
(Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its abstract on the V007 Pivotal ...
Disposable Arteriovenous Cannula Market Overview 2025-2034Luton, Bedfordshire, United Kingdom, May 20, 2025 (GLOBE NEWSWIRE) -- The global disposable arteriovenous (AV) cannula market is growing ...
The government should also establish country-wide dialysis quality standards that specify target Kt/V levels, benchmarks for anemia management, dialysis access (such as AV Fistula), Mineral and ...
Peritoneal dialysis also causes different side effects from hemodialysis, like weight gain and high blood sugar. However, some people may be able to avoid this problem by using nonglucose-based ...
The Arteriovenous (AV) fistula, a surgically constructed link between an artery and a vein, is the gold standard of dialysis access. Read on to learn why it is preferred over other options and how ...
Prompted by our previous success with venipuncture technics for chronic dialysis 3 and disappointed with the external shunt, we considered the possibility of creating an arteriovenous fistula ...
Editorial Archive Hemodialysis Using an Arteriovenous Fistula Published November 17, 1966 N Engl J Med 1966;275: 1134 - 1135 ...
Hemodialysis catheter. If you have an immediate need for hemodialysis, your doctor may suggest using a dialysis catheter until your AV graft or AV fistula has healed.
– ATEV demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis – – Detailed results to be presented ...
Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXessTM, its restorative vascular access conduit aXess is a restorative arteriovenous dialysis conduit which allows ...